- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02115815
A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults
A Phase 1a Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults
Study Overview
Status
Conditions
Detailed Description
A phase 1a, first time in human, double-blind, randomized, placebo-controlled, cohort escalation study evaluating the safety and tolerability of a single ascending intramuscular dose of RSV sF or MEDI7510 or placebo.
Approximately 146 participants will be enrolled at 3 US study centers and randomized in a 5:1 ratio by cohort as described below:
Cohort 1: RSV sF 20 microgram (mcg) (n=20) or placebo (n=4) Cohort 1a: MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A (GLA) + 2% weight per volume stable emulsion (n=20) or placebo (n=4) Cohort 2: RSV sF 50 mcg (n=20) or placebo (n=4) Cohort 2a: MEDI7510 (50 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A (GLA) + 2% weight per volume stable emulsion (n=20) or placebo (n=4) Cohort 3: 80 mcg RSV sF (n=20) or placebo (n=4) Cohort 3a: MEDI7510 (80 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A (GLA) + 2% weight per volume stable emulsion (n=20) or placebo (n=4)
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33143
- Miami Research Associates
-
Orlando, Florida, United States, 32806
- Compass Research
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- Accelovance, Inc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age greater than or equal to 60 years
- Written informed consent and any locally required authorization obtained prior to any protocol related procedures
- Ambulatory or ambulatory with assistance (not institutionalized, bedridden, or homebound
- Weight at or above 110 Pounds (lbs)
- Hemoglobin within normal range for age and gender
Exclusion Criteria:
- History of allergy to any component of the vaccine
- Pregnancy or potential to become pregnant during the study. Females who have had a menstrual period within the 12 months prior to study enrollment or are undergoing any fertility treatment or who plan to undergo fertility treatments during the study period are excluded
- Any unstable chronic medical condition, including one that has resulted in change in therapy (medication or other) in the 30 days prior to randomization or hospitalization in the previous year or might be predicted to result in hospitalization in the year after enrollment. Participant with severe, untreated or uncontrolled underlying medical disease that might either compromise participant safety or affect the ability to assess safety of the investigational product are excluded
- Clinically significant abnormalities in Screening laboratory assessments or Screening electrocardiogram (ECG)
- History of hepatitis B or hepatitis C infection
- Cognitive disorder such that informed consent cannot be obtained directly from the participant
- Previous vaccination against respiratory syncytial virus (RSV)
- History of allergy to eggs in adulthood
- History of or current autoimmune disorder
- Immunosuppression caused by disease, including human immunodeficiency virus (HIV), or medications. Any oral prednisone dosing within 30 days of enrollment or planned dosing within the 360-day follow-up period would disqualify.
- History of splenectomy or of condition affecting splenic function
- History of cancer within preceding 5 years other than treated non-melanoma skin cancer
- Body Mass Index 40 or higher
- Significant infection or other acute illness, including fever over 100 fahrenheit (F) on the day prior to or day of randomization
- Receipt of any nonstudy vaccine within 30 days prior to study dosing or expected receipt of nonstudy vaccine within 30 days after study dosing
- Receipt of any investigational product in the 90 days prior to randomization or expected receipt of investigational product during the period of study follow-up
- Receipt of immunoglobulins or blood products within 4 months of study dosing (120 days) or expected receipt of investigational product during the period of study follow-up
- History of thrombocytopenia or bleeding disorder or use of anticoagulants. Participants receiving drugs with anti-platelet activity such as nonsteroidal antiinflammatory drugs, clopidogrel or aspirin are not excluded
- Expected receipt of antipyretic or analgesic medication on a daily or every other day basis from randomization through 72 hours after receipt of investigational product (IP) [a daily dose of 163 milligram (mg) or higher is not considered a contraindication to enrollment]
- Participants who have significant scarring, tattoos, abrasions, cuts, or infections over the deltoid region of both arms that, in the principle investigator's (PI) opinion, could interfere with evaluation of injection site local reactions
- Concurrent enrollment in another clinical study that involves any invasive clinical procedure, including phlebotomy
- History of alcohol or drug abuse or psychiatric disorder that in the PI's opinion would affect the participants safety or compliance with study
- Employees of individuals directly involved with the conduct of the study, individuals who themselves are involved with the conduct of the study, or immediate family members of such individuals.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Sterile saline for human use from commercial source, liquid
|
Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
|
Experimental: RSV sF 20 mcg
Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
|
Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
|
Experimental: MEDI7510 (20 mcg RSV sF)
Participants will receive single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
|
Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
|
Experimental: RSV sF 50 mcg
Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
|
Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
|
Experimental: MEDI7510 (50 mcg RSV sF)
Participants will receive single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
|
Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
|
Experimental: RSV sF 80 mcg
Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
|
Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
|
Experimental: MEDI7510 (80 mcg RSV sF)
Participants will receive a single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
|
Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Solicited Symptoms
Time Frame: Day 1 to Day 7
|
Solicited symptoms: tenderness or soreness at site of injection, pain at site of injection, fatigue or tiredness, headache, generalized muscle aches, swelling at the site of injection, redness at the site of injection, fever greater than or equal to (>=) 100.4 degrees F by any route from Day 1 to Day 7.
|
Day 1 to Day 7
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
Time Frame: From Day 1 to Day 28
|
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received investigational product.
A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent were events between administration of study product and Day 361 that were absent before treatment or that worsened relative to pretreatment state.
|
From Day 1 to Day 28
|
Number of Participants With Treatment-Emergent Adverse Events of Special Interest (TEAESIs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment-Emergent New Onset Chronic Disease (NOCDs)
Time Frame: From Day 1 to Day 361
|
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received investigational product.
A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent were events between administration of study product and Day 361 that were absent before treatment or that worsened relative to pretreatment state.
An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor.
A NOCD was a newly diagnosed medical condition that is of a chronic, ongoing nature.
It was observed after receiving investigational product and was assessed by investigator as medically significant.
|
From Day 1 to Day 361
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-dose Geometric Mean Titers (GMTs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay
Time Frame: Baseline (Day 1), Day 29, 61, 91, 181, 271 and 361
|
RSV neutralizing antibody titers were measured using green fluorescent protein tagged RSV A 2
|
Baseline (Day 1), Day 29, 61, 91, 181, 271 and 361
|
Post-dose Geometric Mean Fold Rises (GMFRs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay
Time Frame: Day 29, 61, 91, 181, 271 and 361
|
RSV neutralizing antibody titers were measured using green fluorescent protein tagged RSV A 2.
|
Day 29, 61, 91, 181, 271 and 361
|
Percentage of Participants Who Experience a Post-dose Seroresponse to Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay
Time Frame: Day 29
|
Seroresponse defined as a greater than or equal to (>=) 4-fold rise from baseline.
|
Day 29
|
Post-dose Geometric Mean Titers (GMTs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay
Time Frame: Baseline (Day 1), Day 29, 61, 91, 181, 271 and 361
|
Anti F IgG antibodies were determined by a multiplex IgG assay developed on the Meso Scale discovery platform.
|
Baseline (Day 1), Day 29, 61, 91, 181, 271 and 361
|
Post-dose Geometric Mean Fold Rises (GMFRs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay
Time Frame: Day 29, 61, 91, 181, 271 and 361
|
Anti F IgG antibodies were determined by a multiplex IgG assay developed on the Meso Scale discovery platform.
|
Day 29, 61, 91, 181, 271 and 361
|
Percentage of Participants Who Experience a Post-dose Seroresponse to Respiratory Syncytial Virus (RSV) by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay
Time Frame: Day 29
|
Seroresponse defined as a greater than or equal to (>=) 4-fold rise from baseline.
|
Day 29
|
Post-dose Geometric Mean Counts (GMCs) From Baseline of T Cell Response Against Respiratory Syncytial Virus (RSV) by RSV F Enzyme-Linked Immunospot (ELISPOT)
Time Frame: Baseline (Day 1), Day 8 and 29
|
The ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides.
|
Baseline (Day 1), Day 8 and 29
|
Post-dose Geometric Mean Fold Rises (GMFRs) of T Cell Response Against Respiratory Syncytial Virus (RSV) by RSV F Enzyme-Linked Immunospot (ELISPOT)
Time Frame: Day 8 and 29
|
The ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides.
|
Day 8 and 29
|
Percentage of Participants Who Experience a Post-dose 3-fold Cell-mediated Immune Response to RSV F on Day 8
Time Frame: Day 8
|
Seroresponse defined as a greater than or equal to (>=) 3-fold rise from baseline
|
Day 8
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Judith Falloon, MD, MedImmune LLC
- Principal Investigator: Craig Curtis, MD, Compass Research
- Principal Investigator: Steven Bart, MD, Accelovance
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CD-VA-MEDI7510-1134
- BB-IND 15947 (Other Identifier: US FDA)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Syncytial Virus (RSV)
-
University of RochesterActive, not recruitingRespiratory Syncytial Virus (RSV)United States
-
University of OxfordInnovative Medicines Initiative; Respiratory syncytial virus consortium in...Active, not recruitingRespiratory Syncytial Virus (RSV)United Kingdom
-
Enanta Pharmaceuticals, IncCompletedRespiratory Syncytial Virus (RSV)United States
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus (RSV)Belgium
-
NovavaxPATHCompleted
-
Enanta Pharmaceuticals, IncRecruitingRespiratory Syncytial Virus (RSV)United States, Spain, Israel, Australia, Germany, Korea, Republic of, Taiwan, United Kingdom, Argentina, Brazil, New Zealand, Poland, Romania, South Africa, Mexico
-
NovavaxCompletedRespiratory Syncytial Virus (RSV)United States
-
NovavaxCompletedRespiratory Syncytial Virus (RSV)United States
-
VaxartCompletedRespiratory Syncytial Virus (RSV)United States
-
PfizerCompletedRESPIRATORY SYNCYTIAL VIRUS (RSV)United States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States